BACKGROUND AND PURPOSE: Inhibition of the G-protein gated ACh-activated inward rectifier potassium current, IK,ACh may be an effective atrial selective treatment strategy for atrial fibrillation (AF). Therefore, the anti-arrhythmic and electrophysiological properties of a novel putatively potent and highly specific IK,ACh inhibitor, XAF-1407 (3-methyl-1-[5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-d]pyrimidin-6-yl]azetidin-3-ol), were characterised for the first time in vitro and investigated in horses with persistent AF. EXPERIMENTAL APPROACH: The pharmacological ion channel profile of XAF-1407 was investigated using cell lines expressing relevant ion channels. In addition, eleven horses were implanted with implantable cardioverter defibrillators enabling atrial tachypacing into self-sustained AF. The electrophysiological effects of XAF-1407 were investigated after serial cardioversions over a period of 1 month. Cardioversion success, drug-induced changes of atrial tissue refractoriness, and ventricular electrophysiology were assessed at baseline (day 0) and days 3, 5, 11, 17, and 29 after AF induction. KEY RESULTS: XAF-1407 potently and selectively inhibited Kir 3.1/3.4 and Kir 3.4/3.4, underlying the IK,ACh current. XAF-1407 treatment in horses prolonged atrial effective refractory period as well as decreased atrial fibrillatory rate significantly (~20%) and successfully cardioverted AF, although with a decreasing efficacy over time. XAF-1407 shortened atrioventricular-nodal refractoriness, without effect on QRS duration. QTc prolongation (4%) within 15 min of drug infusion was observed, however, without any evidence of ventricular arrhythmia. CONCLUSION AND IMPLICATIONS: XAF-1407 efficiently cardioverted sustained tachypacing-induced AF of short duration in horses without notable side effects. This supports IK,ACh inhibition as a potentially safe treatment of paroxysmal AF in horses, suggesting potential clinical value for other species including humans.
BACKGROUND AND PURPOSE: Inhibition of the G-protein gated ACh-activated inward rectifier potassium current, IK,ACh may be an effective atrial selective treatment strategy for atrial fibrillation (AF). Therefore, the anti-arrhythmic and electrophysiological properties of a novel putatively potent and highly specific IK,ACh inhibitor, XAF-1407 (3-methyl-1-[5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-d]pyrimidin-6-yl]azetidin-3-ol), were characterised for the first time in vitro and investigated in horses with persistent AF. EXPERIMENTAL APPROACH: The pharmacological ion channel profile of XAF-1407 was investigated using cell lines expressing relevant ion channels. In addition, eleven horses were implanted with implantable cardioverter defibrillators enabling atrial tachypacing into self-sustained AF. The electrophysiological effects of XAF-1407 were investigated after serial cardioversions over a period of 1 month. Cardioversion success, drug-induced changes of atrial tissue refractoriness, and ventricular electrophysiology were assessed at baseline (day 0) and days 3, 5, 11, 17, and 29 after AF induction. KEY RESULTS:XAF-1407 potently and selectively inhibited Kir 3.1/3.4 and Kir 3.4/3.4, underlying the IK,ACh current. XAF-1407 treatment in horses prolonged atrial effective refractory period as well as decreased atrial fibrillatory rate significantly (~20%) and successfully cardioverted AF, although with a decreasing efficacy over time. XAF-1407 shortened atrioventricular-nodal refractoriness, without effect on QRS duration. QTc prolongation (4%) within 15 min of drug infusion was observed, however, without any evidence of ventricular arrhythmia. CONCLUSION AND IMPLICATIONS: XAF-1407 efficiently cardioverted sustained tachypacing-induced AF of short duration in horses without notable side effects. This supports IK,ACh inhibition as a potentially safe treatment of paroxysmal AF in horses, suggesting potential clinical value for other species including humans.
Authors: Arne van Hunnik; Dennis H Lau; Stef Zeemering; Marion Kuiper; Sander Verheule; Ulrich Schotten Journal: Heart Rhythm Date: 2015-12-08 Impact factor: 6.343
Authors: Jonas Goldin Diness; Ulrik S Sørensen; Jakob Dahl Nissen; Baha Al-Shahib; Thomas Jespersen; Morten Grunnet; Rie Schultz Hansen Journal: Circ Arrhythm Electrophysiol Date: 2010-06-19
Authors: Jonas Goldin Diness; Lasse Skibsbye; Rafel Simó-Vicens; Joana Larupa Santos; Pia Lundegaard; Carlotta Citerni; Daniel Rafael Peter Sauter; Sofia Hammami Bomholtz; Jesper Hastrup Svendsen; Søren-Peter Olesen; Ulrik S Sørensen; Thomas Jespersen; Morten Grunnet; Bo Hjorth Bentzen Journal: Circ Arrhythm Electrophysiol Date: 2017-10
Authors: Merle Friederike Fenner; Helena Carstensen; Sarah Dalgas Nissen; Eva Melis Hesselkilde; Christine Scott Lunddahl; Maja Adler Hess Jensen; Ameli Victoria Loft-Andersen; Stefan Michael Sattler; Pyotr Platonov; Said El-Haou; Claire Jackson; Raymond Tang; Robert Kirby; John Ford; Ulrich Schotten; James Milnes; Ulrik Svane Sørensen; Thomas Jespersen; Rikke Buhl Journal: Br J Pharmacol Date: 2020-06-24 Impact factor: 8.739
Authors: Aleksei V Mikhailov; Anuradha Kalyanasundaram; Ning Li; Shane S Scott; Esthela J Artiga; Megan M Subr; Jichao Zhao; Brian J Hansen; John D Hummel; Vadim V Fedorov Journal: J Mol Cell Cardiol Date: 2020-10-29 Impact factor: 5.000
Authors: Vladimír Sobota; Giulia Gatta; Arne van Hunnik; Iris van Tuijn; Marion Kuiper; James Milnes; Thomas Jespersen; Ulrich Schotten; Sander Verheule Journal: Front Pharmacol Date: 2021-01-27 Impact factor: 5.810
Authors: Merle Friederike Fenner; Giulia Gatta; Stefan Sattler; Marion Kuiper; Eva Melis Hesselkilde; Ditte M T Adler; Morten Smerup; Ulrich Schotten; Ulrik Sørensen; Jonas Goldin Diness; Thomas Jespersen; Sander Verheule; Arne Van Hunnik; Rikke Buhl Journal: Front Physiol Date: 2021-02-09 Impact factor: 4.566
Authors: Sarah D Nissen; Rikke Weis; Elisabeth K Krag-Andersen; Eva M Hesselkilde; Jonas L Isaksen; Helena Carstensen; Jørgen K Kanters; Dominik Linz; Prashanthan Sanders; Charlotte Hopster-Iversen; Thomas Jespersen; Steen Pehrson; Rikke Buhl Journal: J Vet Intern Med Date: 2022-04-30 Impact factor: 3.175